Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Monotherapy in patients who are contraindicated in the topical use of beta blockers. As an adjunct therapy, along with other drugs that lower the intraocular pressure, if the appropriate intraocular pressure was not achieved during treatment with one drug.
Composition:
1 ml of solution contains 2 mg of brimonidine tartrate (equivalent to 1.3 mg of brimonidine).
Action:
A selective α receptor agonist2-adrenergic for topical use. It lowers intraocular pressure by reducing aqueous humor production and increasing choroidal scleral outflow. Affinity of the drug for α receptors1-adrenergic is 1000 times smaller compared to affinity for α receptors2, thanks to which the drug does not dilate pupils or shrinkage capillaries after human retinal xenografts. The product reduces intraocular pressure, minimally affecting the activity of the cardiovascular and respiratory system. The drug shows a rapid onset of action, and the maximum antihypertensive effect occurs 2 hours after administration. The degree of binding to plasma proteins is approximately 29%. After local administration, apparent T0,5 in the systemic circulation it is about 3 hours. Brimonidine binds reversibly to the melanin of eye tissues without adverse effects. In the absence of melanin, there is no accumulation of the drug.
Contraindications:
Hypersensitivity to brimonidine or other components of the preparation. Do not use in newborns, infants and children under 2 years. Concomitant use of MAO inhibitors and antidepressants that affect noradrenergic prescription (eg tricyclic antidepressants and mianserin).
Precautions:
Brimonidine is not recommended for children between 2 and 12 years of age due to a lack of safety and efficacy studies. If brimonidine is needed in children aged 2-12 years and / or those weighing <20 kg, care should be taken to ensure close observation due to the frequent occurrence of somnolence. Exercise caution in patients with severe or unstable and uncontrolled cardiovascular disease, depression, cerebral or coronary circulation disorders, Raynaud's syndrome, orthostatic hypotension or thromboangiitis obliterans, liver or kidney disease (no experience of use). The preparation should be discontinued if an allergic reaction occurs. The product contains benzalkonium chloride, which may cause eye irritation.
Pregnancy and lactation:
The preparation can be used during pregnancy only if the benefit for the mother outweighs the potential risk to the fetus. It should not be used during breast-feeding.
Side effects:
Very common: headache, drowsiness; eye irritation, including allergic reactions (hyperemia, stinging, stinging, itching, foreign body sensation, conjunctival papules), blurred vision; dry mouth; weariness. Common: dizziness, taste disorders; local irritation (swelling and congestion of the eyelids, blepharitis, conjunctival edema, presence of secretion in the conjunctival sac, pain and tearing), photophobia, erosion and corneal discoloration, dry eye, conjunctivitis, blurred vision, conjunctivitis; symptoms from the upper respiratory tract; gastrointestinal symptoms; asthenia. Uncommon: palpitations / arrhythmias (including bradycardia and tachycardia); dryness in the nose; general allergic reaction; depression. Rarely: shortness of breath. Very rare: fainting; iritis (anterior uveitis), miosis; hypertension, hypotension; insomnia.
Dosage:
Adults: 1 drop into the conjunctival sac of the affected eye (eyes) 2 times a day, every 12 hours. Immediately after instillation of the drug, it is recommended to compress the lacrimal sac in the region of the medial angle of the eye (compressing the tear point) for 1 min.If you use more than one eye medicine, it is recommended that you keep at least 5-15 minutes between each administration.
(C)
